Global Retirement Partners LLC lifted its stake in GlaxoSmithKline plc (NYSE:GSK) by 13.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,516 shares of the pharmaceutical company’s stock after buying an additional 420 shares during the quarter. Global Retirement Partners LLC’s holdings in GlaxoSmithKline were worth $147,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of the company. Wealthcare Advisory Partners LLC boosted its stake in shares of GlaxoSmithKline by 6.6% in the fourth quarter. Wealthcare Advisory Partners LLC now owns 4,020 shares of the pharmaceutical company’s stock worth $154,000 after buying an additional 249 shares during the last quarter. 1832 Asset Management L.P. raised its holdings in GlaxoSmithKline by 35.2% in the 4th quarter. 1832 Asset Management L.P. now owns 967 shares of the pharmaceutical company’s stock worth $37,000 after purchasing an additional 252 shares during the period. Reilly Financial Advisors LLC raised its holdings in GlaxoSmithKline by 36.7% in the 1st quarter. Reilly Financial Advisors LLC now owns 950 shares of the pharmaceutical company’s stock worth $36,000 after purchasing an additional 255 shares during the period. Courier Capital LLC raised its holdings in GlaxoSmithKline by 3.0% in the 4th quarter. Courier Capital LLC now owns 9,025 shares of the pharmaceutical company’s stock worth $345,000 after purchasing an additional 260 shares during the period. Finally, grace capital raised its holdings in GlaxoSmithKline by 2.7% in the 4th quarter. grace capital now owns 9,833 shares of the pharmaceutical company’s stock worth $376,000 after purchasing an additional 263 shares during the period. Hedge funds and other institutional investors own 11.12% of the company’s stock.
In other news, Director Plc Glaxosmithkline bought 325,000 shares of GlaxoSmithKline stock in a transaction on Monday, April 22nd. The stock was acquired at an average price of $18.00 per share, with a total value of $5,850,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.00% of the stock is owned by corporate insiders.
Shares of GlaxoSmithKline stock opened at $39.46 on Friday. GlaxoSmithKline plc has a 12 month low of $36.41 and a 12 month high of $42.36. The company has a market cap of $97.88 billion, a price-to-earnings ratio of 12.49, a PEG ratio of 2.04 and a beta of 0.74. The company has a quick ratio of 0.48, a current ratio of 0.72 and a debt-to-equity ratio of 6.92.
The company also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be issued a dividend of $0.4953 per share. The ex-dividend date is Thursday, May 16th. This represents a $1.98 dividend on an annualized basis and a dividend yield of 5.02%. GlaxoSmithKline’s payout ratio is currently 61.71%.
COPYRIGHT VIOLATION WARNING: “Global Retirement Partners LLC Buys 420 Shares of GlaxoSmithKline plc (GSK)” was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/05/19/global-retirement-partners-llc-buys-420-shares-of-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: Outstanding Shares, Buying and Selling Stocks
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.